KCM
PGNX

Kingdon Capital Management’s Progenics Pharmaceuticals Inc PGNX Stock Holding History

Kingdon Capital Management’s Portfolio PGNX Stock Details PGNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q3 		– Sell
-580,000
Closed -$2.58M – 238
2013
Q2 		$2.58M Buy
+580,000
New +$2.6M 0.15% 151

Other funds holding PGNX

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return
HCMT
Highland Capital Management (Texas) Dallas, Texas $39M AUM
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Kingdon Capital Management's PGNX Position: Q3 2013 in Review

Kingdon Capital Management sold out of Progenics Pharmaceuticals Inc (PGNX) in Q3 2013, closing a stake of 580,000 shares — an estimated $2.58M sold.

Kingdon Capital Management first reported a position in PGNX in Q2 2013 and held it in 1 quarter. The position peaked at $2.58M in Q2 2013. 83 funds tracked by Wall St. Rank hold PGNX as of Q3 2013.

  • Kingdon Capital Management reported no remaining Progenics Pharmaceuticals Inc position as of Q3 2013 after selling out during the quarter.
  • Kingdon Capital Management sold 580,000 Progenics Pharmaceuticals Inc shares in Q3 2013, an estimated $2.58M.
  • Kingdon Capital Management first reported a position in Progenics Pharmaceuticals Inc in Q2 2013 and held it in 1 quarter.
  • Kingdon Capital Management's Progenics Pharmaceuticals Inc position peaked at $2.58M in Q2 2013.
  • 83 funds tracked by Wall St. Rank held Progenics Pharmaceuticals Inc as of Q3 2013.

Based on Kingdon Capital Management's 13F filing for Q3 2013, filed 14 Nov 2013.